Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cicatridina is a brand of tissue-repair and wound-healing products developed by Farma-Derma and distributed in various markets, including Switzerland by Hygis. The primary active ingredient is hyaluronic acid (as sodium hyaluronate), a mucopolysaccharide that serves as a structural component of the extracellular matrix. Hyaluronic acid facilitates tissue repair by providing hydration and creating a scaffold for cell migration and proliferation. Cicatridina is most commonly marketed as vaginal ovules for the treatment of atrophic vaginitis and vaginal dryness, but it is also available in spray and ointment forms for topical wound healing, surgical scars, and proctological conditions. The formulation often includes botanical extracts such as *Aloe vera*, *Calendula officinalis*, and *Centella asiatica* to provide additional soothing and anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cicatridina.